NASDAQ:GBT Global Blood Therapeutics (GBT) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free GBT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$68.49▼$68.4950-Day Range$68.07▼$68.4952-Week Range$21.65▼$73.02Volume74 shsAverage Volume2.07 million shsMarket Capitalization$4.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Global Blood Therapeutics alerts: Email Address Ad Paradigm Press8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency About Global Blood Therapeutics Stock (NASDAQ:GBT)Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Read More Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> GBT Stock News HeadlinesFebruary 5, 2024 | forbes.comHow Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 BillionDecember 27, 2023 | msn.comUS biotech firm addresses critical gap in blood pressure managementMarch 18, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.December 20, 2023 | bbc.comShould we pay people for donating blood?November 13, 2023 | bizjournals.comA serial biotech company founder has Parkinson's. His latest company is targeting a potentially game-changing therapyNovember 8, 2023 | skift.comAmex GBT Sees More Small Companies Needing Business Travel HelpNovember 8, 2023 | finance.yahoo.comGBT Technologies Cancels and Voids Reverse Stock SplitOctober 6, 2023 | finance.yahoo.comGlobal Peripheral Blood Mononuclear Cells Research Report 2023: R&D Revolution - PBMCs Paving the Way for Medical BreakthroughsMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.September 28, 2023 | benzinga.comDiabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This TrajectoryJuly 28, 2023 | finance.yahoo.comPFE Mar 2024 32.500 callJune 17, 2023 | benzinga.comGout Therapeutics Market Challenges, Drivers, Growth Opportunities, and Major Company Profiles 2023June 14, 2023 | finance.yahoo.comGlobal Patient Blood Management Market to Reach $23.6 Billion by 2030June 12, 2023 | finance.yahoo.comGlobal Lymphoma Therapeutics Market Report 2023: Sector is Expected to Reach $24.9 Billion by 2029 at a CAGR of 7.8%June 11, 2023 | finance.yahoo.comGlobal Health Study Validates Biospectal OptiBP Mobile Blood Pressure Measurement App Accuracy Across Diverse SettingsJune 7, 2023 | bizjournals.comTed Love, now the chair of biotech's big trade group, talks drug access, leadership and 'crazy' co-paysJune 6, 2023 | finance.yahoo.comGBT Received a Notice of Allowance for its Microchip Reliability Verification and Auto-Correction Patent ApplicationJune 4, 2023 | es-us.finanzas.yahoo.comThe Global Non-insulin Diabetes Therapeutics MarketMay 23, 2023 | msn.comPfizer Announces $5.4 Billion Deal to Acquire Global Blood TherapeuticsMay 17, 2023 | marketwatch.com(2023-2030) Anemia Drugs Market Size, Share and Trend Analysis Report, Worldwide Opportunities, Demand ForecastMay 11, 2023 | marketwatch.comArtificial Blood Market, Global Outlook and Forecast 2023-2029May 5, 2023 | marketwatch.com2030 Blood Cancer Therapeutics Market Forecast: Positive Growth Trajectory AheadMay 5, 2023 | finance.yahoo.comRare Disease Therapeutics Global Market Report 2023: Increasing Number of Patients with Rare Diseases Bolsters GrowthMay 5, 2023 | finance.yahoo.comMonoclonal Antibody Therapeutics Market to Surpass US$ 534.26 Billion by 2030, Says Coherent Market Insights (CMI)May 5, 2023 | marketwatch.comMetabolic Disorder Therapeutics Market 2023 Set to Growth Highest CAGR and Revenue by 2030May 4, 2023 | finance.yahoo.comGlobal Antimicrobial Therapeutics Market Report 2023-2027: Sector to Grow by $51.4 Billion at a 5.63% CAGRApril 27, 2023 | finance.yahoo.comProstate Cancer Therapeutics Global Market Report 2023: Launch of Emerging Novel Therapies Brings MomentumSee More Headlines Receive GBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GBT CUSIPN/A CIK1629137 Webwww.gbt.com Phone(650) 741-7700FaxN/AEmployees457Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-303,090,000.00 Net Margins-137.30% Pretax Margin-137.01% Return on Equity-170.37% Return on Assets-39.24% Debt Debt-to-Equity Ratio4.92 Current Ratio6.88 Quick Ratio6.17 Sales & Book Value Annual Sales$194.75 million Price / Sales23.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book22.46Miscellaneous Outstanding Shares67,476,000Free Float64,170,000Market Cap$4.62 billion OptionableOptionable Beta0.45 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Ted W. Love M.D. (Age 63)Pres, CEO & Director Comp: $1.06MMr. Jeffrey S. Farrow (Age 60)CFO & Principal Accounting Officer Comp: $672.67kMs. Jung E. Choi (Age 52)Chief Bus. & Strategy Officer Comp: $645kMr. David L. Johnson (Age 53)Chief Commercial Officer Comp: $661.5kDr. Kim Smith-Whitley M.D. (Age 61)Exec. VP and Head of R&D Comp: $654kDr. David R. PhillipsFounder & AdvisorDr. Matthew P. Jacobson Ph.D.Founder & AdvisorDr. Andrej Sali Ph.D.Founder & AdvisorMs. Nazila Habibizad (Age 59)Exec. VP of Operations Stephanie YaoSr. Director of Corp. Communications & Investor RelationsMore ExecutivesKey CompetitorsOrganon & Co.NYSE:OGNAlkermesNASDAQ:ALKSBiohavenNYSE:BHVNBridgeBio PharmaNASDAQ:BBIOPerrigoNYSE:PRGOView All Competitors GBT Stock Analysis - Frequently Asked Questions How were Global Blood Therapeutics' earnings last quarter? Global Blood Therapeutics, Inc. (NASDAQ:GBT) released its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.03. The firm had revenue of $52.05 million for the quarter, compared to the consensus estimate of $53.69 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 170.37% and a negative net margin of 137.30%. The firm's revenue was up 41.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.97) EPS. What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO? 20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend. What other stocks do shareholders of Global Blood Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ). When did Global Blood Therapeutics IPO? (GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers. This page (NASDAQ:GBT) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Blood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.